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ABSTRACT 
~z~I-labeled  human  epidermal  growth  factor  (hEGF)  binds  in  a  specific  and 
saturable  manner to human fibroblasts.  At 37~  the  cell-bound  ~25I-hEGF  ini- 
tially  may be  recovered  in  a  native  form by  acid  extraction;  upon  subsequent 
incubation, the cell-bound ~25I-hEGF  is degraded very rapidly, with the  appear- 
ance in the medium of 125I-monoiodotyrosine. At 0~  cell-bound nSI-hEGF is not 
degraded but slowly dissociates from the cell. 
The data are consistent with a mechanism in which ~zSI-hEGF initially is bound 
to  the  cell  surface  and  subsequently  is  internalized  before  degradation.  The 
degradation  is  blocked  by  inhibitors  of  metabolic  energy  production  (azide, 
cyanide, dinitrophenol), some protease inhibitors (Tos-Lys-CH2CI, benzyl guani- 
dobenzoate),  a  lysosomotropic  agent  (chloroquine),  various  local  anesthetics 
(cocaine, lidocaine, procaine), and ammonium chloride. 
After the binding and degradation of ~25I-hEGF, the fibroblasts are no longer 
able to rebind fresh hormone. The binding capacity of these cells is restored by 
incubation in  a  serum-containing medium; this restoration is inhibited by cyclo- 
heximide or actinomycin D. 
Human epidermal growth factor (hEGF) is a poly- 
peptide  (mol  wt  approximately  5,400)  that  has 
been  purified  from human pregnancy urine  (6). 
hEGF exhibits the biological activities ascribed to 
mouse-derived  EGF (mEGF) and competes in a 
specific manner with 125I-labeled mEGF for bind- 
ing  to  human  fibroblasts.  However,  the  amino 
acid compositions and immunological and electro- 
phoretic properties of human and mEGF are not 
identical,  hEGF,  therefore,  appears  to  be  an 
evolved  form of the  mouse-derived  polypeptide, 
retaining  the  specificities required  for binding  to 
cells and for exerting  its biological effect. 
A  new aspect  of the biology  of EGF recently 
has  emerged  with the  publication  of the  amino 
acid sequence and disulfide linkages of the human 
urinary  hormone  urogastrone  (17).  Of  the  53 
amino acid  residues  comprising  the  urogastrone 
and  mEGF molecules,  37  are  common to both 
peptides,  and the three disulfide bonds are formed 
in  the  same  relative  positions.  Furthermore, 
mEGF has been shown to possess gastric antise- 
cretory activity,  and  urogastrone  to  possess  the 
biological activity of EGF as judged by its ability 
to  induce  precocious  eye  opening  in  newborn 
mice. The results suggest that hEGF and urogas- 
trone may be identical  molecules. 
hEGF is a potent mitogen for human fibroblasts 
in  cell culture,  stimulating  both the  synthesis  of 
DNA and cell proliferation  (3). Although the abil- 
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ents, the synthesis of cellular macromolecules, and 
cell division has been described (see references 4 
and 28 for review), little is known about the initial 
interaction of these mitogens with the cell surface. 
Since the binding of macromolecular  mitogens to 
the cell membrane  is thought  to be  the first step 
necessary for their biological activity, it is impor- 
tant to define the biochemical events which occur 
during and subsequent to the interaction of mito- 
gens  with  the  cell  surface.  This  report  examines 
the binding and metabolic fate of the bound hor- 
mone. 
MATERIALS  AND  METHODS 
hEGF 
hEGF was purified (6) from a urinary protein powder 
obtained from pregnant women. 
Antiserum to hEGF 
Rabbit antibody to hEGF was prepared, according to 
the procedure previously described (5),  with a  total of 
approximately  100  /zg of hEGF.  The gamma globulin 
fraction was purified by DEAE chromatography (12). 
Iodination of hEGF and Antiserum 
The  iodination  (22)  of hEGF and of the antiserum 
(gamma globulin fraction) was carried out using a molar 
ratio of protein to Na1251 of approximately 2:1. hEGF (2 
/zg) was dissolved in 20 ~,1 of 0.05 M phosphate buffer 
pH 7.5, and added to 20/~1 of 0.5 M phosphate buffer, 
pH 7.5, containing 0.4 mCi of carrier-free NanSI. Chlor- 
amine T (20/zg in 10/zl) was then added. The reaction 
was stopped in 25 s by the addition of sodium metabisul- 
fite (40 ~g in 10/~1). The labeled protein was separated 
from unreacted Na~I by gel filtration through Sephadex 
G-25  with a  buffer containing 0.05  M  phosphate, pH 
7.5,  and 0.075  M  sodium chloride. The labeled hEGF 
was stored frozen in the presence of 0.1% albumin. The 
specific activity of the hE GF was 120,000-145,000  cpm/ 
ng and of the antibody, 3,500 cpm/ng. 
Autoradiography 
The  cells,  after  incubation  with  nSI-labeled  hEGF, 
were  washed  free  of  unbound  radioactivity  and  were 
fixed with 2% glutaraldehyde in phosphate buffer, pH 
7.3, for 30 min at room temperature. After rinsing with 
water, the dishes were coated with NTB2  emulsion for 
autoradiography (1). 
Cell Culture 
Monolayer cultures of human foreskin fibroblasts (HF 
cells) were derived from explants of newborn foreskin 
and were grown in Dulbecco's Modified Eagle Medium 
modified to contain 20 mM N-2-hydroxyethylpiperazine- 
N-2-ethanesulfonic acid (HEPES),  1.1  g/liter NaHCO3, 
and chlortetracyeline (50  /zg/ml). The final pH of this 
medium  (DM  medium)  was  7.4.  Stock  cultures  were 
maintained in the DM medium supplemented with 10% 
fetal calf serum. 
To prepare experimental cultures, approximately 2  x 
105  ceils were inoculated  into replicate 60-mm Falcon 
culture dishes (Falcon  Plastics, Div.  of BioQuest,  Ox- 
nard, Calif.) which contained 5 ml of DM medium sup- 
plemented with 10% calf serum. The cultures were incu- 
bated  at  37~  in  a  humidified  CO2  incubator  until  a 
confluent monolayer of cells was formed. Cell counts, as 
determined  with  a  Coulter  counter,  showed  that  the 
confluent monolayers contained approximately  1  ￿  106 
cells per dish and that there was a  variance of 10%  or 
less in cell numbers per dish in the replicate cultures used 
in a given experiment. 
The  human  fibroblasts  used  in  this  study  were  be- 
tween the 9th and  17th  passages in culture  (split ratio 
1:4).  Cells were subcultured by trypsinization (18). 
1251-hEGF Binding Assay 
Confluent  monotayer  cultures  of  HF  cells  were 
washed twice with 4-ml portions of prewarmed Hanks' 
solution, and 1.4 ml of prewarmed binding medium were 
added to each dish. The  binding medium consisted of 
DM  medium  plus  bovine  serum  albumin  (0.1%)  and 
Gentamicin (50/zg/ml). Labeled hEGF or other compo- 
nents as specified in the text were added to a final vol of 
1.5 ml. After incubation at 37~  unbound radioactivity 
was removed by washing the cell monolayer eight times 
with a  total of  13  ml  of cold  (0~  '  solution 
containing bovine serum albumin (0.1%). To solubilize 
the cells,  1.5  ml of 0.5  N  NaOH  were added to each 
dish, and the dishes were incubated at 37~  for 1 h. The 
contents of the dishes were transferred to counting vials, 
and the radioactivity was measured with a Nuclear Chi- 
cago  gamma-spectrometer  (Nuclear-Chicago,  Des 
Plaines,  Ill.).  Nonspecific  binding,  as  determined  by 
measuring the  binding in  the presence of excess unla- 
beled mEGF (20/zg/dish), amounted to less than 2% of 
the total label bound. All experiments were performed in 
duplicate or triplicate. 
Gel filtration 
To analyze the nature of radioactive material released 
into  the  binding  medium,  we  lyophilized the  ceil-free 
medium and resuspended the material in 0.5 ml of wa- 
ter. Each sample was chromatographed on a column (1.5 
x  35 cm) of Bio-Gel P-10 (200-400 mesh) equilibrated 
with  0.1  M  ammonium  acetate.  Fractions of approxi- 
mately 2 ml were collected. 
The  radioactivity  that  remained  bound  to  cells was 
extracted  by  adding  1.5  ml  of 0.1  N  HC1  containing 
0.1%  bovine serum albumin to the monolayer of cells 
and  incubating  at  room  temperature  for  90  min.  The 
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tal  cell-bound  radioactivity,  was  lyophilized,  resus- 
pended  in  0.1  M  ammonium  acetate  and  chromato- 
graphed on the Bio-Gel column as described above. 
Paper Chromatography 
Ascending paper chromatography was carried out us- 
ing  Whatman  No.  3MM  paper,  42  cm  in  length.  A 
ninhydrin spray (Nutritional Biochemicals Corp., Cleve- 
land, Ohio) was used for detection. 
Materials 
Dulbecco's Modified Eagle medium, fetal calf serum, 
calf serum, trypsin, and chlortetracycline were obtained 
from Grand Island Biological Co., Grand Island, N. Y. 
Gentamicin and Hanks' balanced salt solution were pur- 
chased from Microbiological Associates, Inc., Bethesda, 
Md. Purified mouse-derived EGF was prepared as previ- 
ously described (31). Bovine brain and pituitary fibro- 
blast  growth  factors  (FGF),  multiplication stimulating 
activity (MSA), somatomedin C,  and  somatomedin B 
were generous gifts from Doctors Denis Gospodarowicz 
(The Salk Institute, San Diego, Calif.), Howard Temin 
(University of Wisconsin, Madison, Wis.), Judson Van 
Wyk  (University of North  Carolina,  Durham,  N.C.), 
and  KABI  Chemical Company,  Sweden,  respectively. 
Procaine hydrochloride and chloroquine were obtained 
from  Sigma  Chemical  Co.,  St.  Louis,  Mo.  Lidocaine 
hydrochloride was a  product of ASTRA,  and cocaine 
hydrochloride,  a  product  of  Mallinckrodt.  Cyclohexi- 
mide was purchased from Nutritional Biochemicals and 
HEPES  and  Actinomycin  D  from  Calbiochem,  San 
Diego, Calif. Bovine serum albumin was purchased from 
Miles Laboratories, Inc. NanSI was obtained from New 
England  Nuclear  Corp.,  Boston,  Mass.  Nuclear  track 
emulsion  Type  NTB2,  developer  D-76,  fixative,  and 
chloramine T  were  products of  Eastman Kodak  Co., 
Rochester, N. Y. 
RESULTS 
Time- Course of Binding 
The time-course of binding of 12~I-hEGF to hu- 
man fibroblasts at 37~  and 0~  is shown in Fig. 1. 
Maximal binding was reached after incubations of 
30-40 rain at 37~  or approximately 2.5 h  at 0~ 
The maximal amount of hormone bound at 37~ 
was  approximately  twice  that bound  at  0~  On 
continued incubation of the labeled hormone with 
HF cells at 37~  the amount of cell-bound radio- 
activity  decreased  until  a  constant  level  of  15- 
20%  of the initial maximal amount of cell-bound 
radioactivity  remained  associated  with  the  cells. 
When  the  cells  were  incubated  with  the  labeled 
hormone  at  0~  there  was  no  net  loss  of  cell- 
bound radioactivity. 
The  following  experiments  were  conducted  to 
determine the basis for the loss of cell-bound ra- 
dioactivity  during  incubation  of  125I-hEGF  with 
HF cells at 37~  Labeled hormone was incubated 
with  cells  for  6  h  at  37~  the  medium  was  re- 
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FIGURE  1  Time-course  of  ~zSI-hEGF binding to  human fibroblasts at  37  ~ and  0~  125I-hEGF  (final 
concentration 4  ng/ml, 2,4,400  cpm/ng) was added to each culture dish containing the standard binding 
medium (1.5  ml for the 37~  experiments and 2.0 ml for the 0~  experiments). At the indicated time 
intervals, duplicate dishes were  selected and the cell-bound radioactivity was  determined as described 
under Materials and Methods. 
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and  the  binding  of the  hormone  in  this  "used" 
medium  to  fresh  cells was  determined  (Table  I, 
exp 4). The results showed that the hormone re- 
maining in the medium was fully active in binding 
to fresh cells, indicating that extensive degradation 
or  inactivation  of  free  hormone  in  the  binding 
medium had  not occurred. In addition, cells that 
had  been  incubated  for  6  h  at  37~  with  the 
hormone  and  then  washed  were  unable  to  bind 
fresh hormone (Table  I, exp  3).  Control experi- 
ments  showed  only  a  slight  decrease  (10%)  in 
hEGF-binding capacity  during  incubation  in  the 
binding medium in the absence of hEGF (Table I, 
exp  5).  The  decrease  in  cell-bound radioactivity 
which  occurred  at  37~  in  the  presence  of  the 
hormone was apparently due to the loss of a cellu- 
lar function (plasma membrane receptors?) neces- 
sary for hormone binding. 
The pattern of binding of 1zSI-hEGF to HF cells 
was examined using modifications of the standard 
albumin-containing medium. A  time-course simi- 
lar to that illustrated in Fig. 1 was observed when 
the binding medium was altered to contain either 
2%  or  10%  calf serum,  although in  10%  serum 
the final steady-state level reached was 35% of the 
initially bound  radioactivity rather  than  the  15- 
20%  attained  in  the  standard  medium  (data  not 
shown). 
The  addition  of  cycloheximide (20  /~g/ml)  to 
the standard binding medium depressed the maxi- 
mal level of binding by 24% but did not otherwise 
significantly  alter  the  pattern  shown  in  Fig.  1. 
These results suggest that protein synthesis is not 
necessary  for  either  the  initial  binding  of  1251- 
hEGF or the  subsequent  decrease  in  cell-bound 
radioactivity. 
Effect of hEGF Concentration on Binding 
The effect of increasing concentrations of hEGF 
on the binding of 125I-hEGF to HF cells is shown 
in Fig. 2. These data show that the binding reac- 
tion is a saturable process with maximal binding at 
approximately 8  ng/ml (1.5  ￿  10 -9 M)  and  half 
maximal binding at 1.8 ng/ml (3.3  ￿  10 -1~ M). At 
the  lowest  (0.04  ng/ml)  and  highest  (20  ng/ml) 
concentrations of hEGF tested, 18.1% and 2.3%, 
respectively, of the  hormone  were  bound  under 
these conditions. 
Specificity  of hEGF Binding 
It  has  been  reported  (2)  that  neither  insulin, 
prolactin,  growth  hormone,  follicle-stimulating 
TABLE  I 
hEGF-Med~d Loss ofHormone-Binding Capacity 
Exp no.  Cell-bound radioactivity 
~m/d~h 
1  6,240 
2  1,235 
3  1,219 
4  6,728 
5  5,583 
The binding of labeled hEGF to confluent HF cells was 
determined  after  1zSI-hEGF (4  ng/ml, 21,900  cpm/ng) 
was incubated with replicate cultures at 37~  for 40 rain 
(exp 1) or 6 h (exp 2). After the 6-h incubation period in 
exp  2,  the  cells  were  washed,  ~251-hEGF (4  ng/ml, 
21,900 cpm/ng) was added, and the cells were incubated 
for  40  min  (exp  3).  After the  6-h  incubation  with a 
second set of cultures in exp 2, the medium was trans- 
ferred to fresh HF cells for a 40-min binding period (exp 
4).  Control cultures were incubated in the binding me- 
dium in the absence of hEGF for 6 h, and the capacity of 
the  cells to  bind ~25I-hEGF under  standard  (40  min) 
binding conditions was determined  (exp 5). 
hormone,  thyrotropin,  nor glucagon was  able  to 
compete with 1251-labeled mouse EGF in the fibro- 
blast receptor assay.  Human  EGF, however, has 
been  shown  to be  an  effective competitor of the 
mouse-derived hormone (6). The data in Table II 
show that,  when human  EGF is used as the  ~25I- 
labeled ligand, none of the polypeptide mitogens 
tested (FGF, MSA, somatomedins B and  C) was 
able  to  compete  for  the  fibroblast  receptor.  As 
expected, mEGF was  an  effective competitor of 
the ~:~I-labeled  hEGF. 
Autoradiography of Cell-Bound 1251-hEGF 
The  binding  of  125I-labeled hEGF  to  HF  cells 
after a 40-min incubation at 37~  in the presence 
and absence of a large excess of unlabeled mEGF 
is shown in Fig. 3. The binding reaction was spe- 
cific as evident by the absence of radioactive grains 
in  the  cells  incubated  with  unlabeled  hormone 
(Fig. 3a). The pattern  of cell-bound radioactivity 
presented in Fig. 3b  was typical of all cells incu- 
bated with  the labeled hormone. Although it was 
not possible from these data to determine whether 
the radioactivity was  on the surface of the cell or 
internalized,  the  radioactivity  appeared  to  be 
rather  uniformly distributed,  and  all  of the  cells 
were labeled. 
Nature of the Cell-Bound IzsI-hEGF 
The cell-bound ~2Sl-hEGF, after acid extraction, 
was  examined by gel filtration and  tested for its 
162  THE  JOURNAL OF  CELL BIOLOGY"  VOLUME 71,  1976 m""  16 
,_o 
Q. 
% 
o.  8 
g, 
.c 
i 
r 
I  I  I  I  I  I  I  I  I  I 
0  4  8  12  16  20 
t25I-hEGF  (ng/ml) 
FmURE 2  Effect of nSI-hEGF concentration on binding to human fibroblasts.  Indicated concentrations 
of labeled hEGF (25,300 cpm/ng) were added to culture dishes and the specific binding was determined 
after a 40-rain incubation at 37~  as described under Materials and Methods. 
TAaLE II 
Specificity of Binding of ~I-hEGF 
Specific 
binding of 
Addition  Concn.  n~I-hEGF 
b~g/ml  cpmldish 
None  10,276 
mEGF  1.0  146 
FGF (brain)  6.7  10,792 
FGF (pituitary)  6.7  10,822 
Somatomedin B  1.0  9,857 
Somatomedin C  1.4  9,680 
MSA  10.0  9,522 
The indicated polypeptides were added simultaneously 
with Iz~I-hEGF (0.8 ng/ml, 53,700 cpm/ng) to HF cells 
in the standard  binding assay  (see Materials and Meth- 
ods). The cell-bound radioactivity was determined after 
a 40-min incubation period at 37"C. 
ability  to  rebind  to  fibroblasts.  After  a  40-min 
binding  period  at  37~  with  labeled  hEGF,  the 
cells were extracted with 0.1  N  HC1.  80%  of the 
radioactivity was extracted by this procedure, and, 
of this  amount,  98%  was of the same  molecular 
weight as  native  hEGF as  determined  by the gel 
filtration  procedure  (see  Materials  and  Methods 
and  reference  2).  After  a  30-min  "washout  pe- 
riod"  at  37~  in  binding  medium  lacking  ~2sI- 
hEGF, approximately 92%  of the remaining cell- 
bound radioactivity was still in the high molecular 
weight form. Thus, low molecular weight products 
of ~2SI-hEGF degradation  do not appear to accu- 
mulate in the cell. 
The ability of the cell-bound ~25I-hEGF to bind 
receptors  on  fresh  fibroblasts  was  examined.  In 
the  first  experiment,  ~25I-hEGF  was  allowed  to 
bind to fibroblasts for 15  min at 37~  before acid 
extraction; in the second experiment, after the 15- 
min  binding  period  the  hormone  was  removed 
from the medium and the cells were incubated for 
35  min before extraction.  The results  (Table  III) 
show that the ]zSI-hEGF which bound to the fibro- 
blasts in the initial 15-min binding period could be 
extracted from the cells and was able to rebind to 
fresh cells with an affinity almost identical to that 
of the  native  hormone  (compare  extract  A  with 
native  ~25I-hEGF).  Upon  longer  incubation,  the 
cell-bound  radioactivity  (extract  B),  although 
mainly  in  a  high-molecular  weight  form,  had  a 
considerably reduced ability to bind to fresh fibro- 
blasts.  Therefore,  some  or  all  of the  cell-bound 
high-molecular  weight  ~25I-hEGF was  altered,  in 
an as yet undetermined manner, during the degra- 
dation period. 
Release and Degradation  of Cell- 
Bound  12~I-hEGF 
To  measure  the  release  of  cell-bound  ~2sI- 
hEGF, we incubated monolayers of HF cells with 
labeled hormone  for an  indicated  period of time 
and then extensively washed  them to remove un- 
CARPF.NTEn AND  COHEN  ~251-Labeled  Human Epidermal Growth Factor  163 FIGURE 3  Autoradiography  of cell-bound t251-hEGF. Labeled hEGF (3.5 ng/ml, 145,000 cpm/ng) was 
added to sparse cultures of human fibroblasts in the standard binding medium (a) in the presence and (b) in 
the absence of unlabeled mEGF (10/zg/ml). After a 40-min binding period at 37~  the cells were washed, 
fixed with glutaraldehyde, covered with a layer of NTB-2 emulsion, and exposed for approximately 6 wk 
(see Materials and Methods). The bar represents 25 ~m.  x  400. 
TABLE III 
Nature of Cell-Bound ~I-hEGF 
aSl-labeled ma-  Radioactivity  Cell-bound  ra-  Percentage cell- 
tefial added  added  dioactivity  bound 
cpm/dish  cpm/dish  % 
Native  ~I-hEGF  12,900  1,350  10.5 
27,400  2,700  9.9 
57,800  5,330  9.2 
Extract A  12,000  1,430  11.9 
24,200  2,360  9.8 
Extract B  27,700  1,160  4,2 
mI-hEGF  (3.2  ng/ml,  82,200 cpm/ng)  was allowed to  bind  to  confluent 
cultures of HF cells at 37"C for 15 rain in the standard binding medium, and 
the cells were washed free of unbound  radioactivity. In one set of cultures, 
the cell-bound radioactivity immediately was extracted by the HCI procedure 
(see Materials and Methods) with a  75% recovery. The extract (extract A) 
was lyophilized and then dissolved in standard binding medium. In a second 
set  of cultures,  fresh  binding  medium  was added  and the  cell-bound  ~sI- 
hEGF was allowed to degrade for 35 rain at 37~  The cell-bound radioac- 
tivity  (56%  of that  initially bound)  then  was  extracted  with  HCI  with  a 
recovery of 86%. This extract (extract B) was lyophilized and then dissolved 
in standard binding medium. The extract A material, the extract B material, 
and  native  nSl-hEGF  were  assayed  for  their abilities to  bind  to  HF cells 
during a standard binding reaction at 37~C for 40 min. 
bound hormone. Binding medium without hEGF 
was added to the cell monolayer, and the amount 
of cell-bound radioactivity was determined at var- 
ious times thereafter. The data in Fig. 4 (curve A) 
show  that,  following incubation  with  12SI-hEGF 
for 40  min at 37~  and removal of the unbound 
hormone in the medium, cell-bound radioactivity 
decreased rapidly (t  t  -  20 min) during the subse- 
quent  incubation  at  37~  After  2-h  incubation 
under these conditions, over 85-95% of the initial 
cell-bound  radioactivity  was  not  associated  with 
the  cells,  and,  upon  the  addition  of  fresh  t25I- 
hEGF,  only  a  small  fraction,  10-20%,  of  the 
original binding capacity could be detected (data 
not shown). 
The data  in  Fig. 4  (curve B)  show the  loss of 
cell-bound  radioactivity  from  HF  cells  preincu- 
bated with t2~I-hEGF for 2 h at 0~  washed, and 
reincubated  at  0~  Under these  conditions,  the 
amount  of  cell-bound  radioactivity  slowly  de- 
creased until approximately 50-60% of the initial 
cell-bound  material  was  released  from  the  cells 
after 4-6 h. 
The nature of the radioactive material released 
into the medium at both 37~  and 0~  (Fig. 4) was 
determined  by  gel  filtration  using  Bio-Gel P-10 
(2).  Two peaks of radioactivity were detected:  a 
high molecular weight fraction the elution volume 
of which corresponded to that of intact IzSI-hEGF, 
and a  low molecular weight fraction with an  elu- 
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rosine. The distribution of the cell-released radio- 
activity in  these  two  fractions  under  the  varying 
experimental  conditions  is  shown  in  Table  IV. 
Essentially all of the radioactivity released at 0~ 
had the same elution volume as intact ~25I-hEGF; 
however,  at  37~  most  of  the  radioactivity  re- 
leased was of low molecular weight form. This low 
molecular  weight  material  was  identified  as  80- 
85%  [lZSI]monoiodotyrosine  and  5-10% 
[lzsI]diiodotyrosine on the basis of co-chromatog- 
raphy  on  paper  with  mono-  and  diiodotyrosine 
standards  in  a  butanol-acetic  acid-water 
(210:63:180)  solvent system. These data indicate 
that,  whereas at 0~  cell-bound  ~25I-hEGF disso- 
ciates from the cell as an intact molecule, at 37~ 
most  of the  cell-bound  a25I-labeled hEGF is  rap- 
idly  degraded  before  the  release  of radioactivity 
from the cells. The degradation of cell-bound ~z~I- 
hEGF at  37~  is similar to the results previously 
obtained  with  ~2SI-labeled  mEGF  (2),  although 
the  rate  of degradation  of human  EGF  is  more 
rapid. 
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FIGURE 4  Dissociation of cell-bound I~I-hEGF under 
varying temperature conditions. Curve A: ~2~I-hEGF (6 
ng/ml, 21,200 cpm/ng) was preincubated with fibroblasts 
for 40 min at 37~  The cells then were washed, and 1.5 
ml  of  standard  binding  medium  were  re-added.  The 
cultures  were incubated  at  37~  and  at  the  indicated 
time  intervals  the  cell-bound  radioactivity  was  deter- 
mined.  Curve B: Identical to curve A, except that the 
initial binding period was 2 h at 0~  and the dissociation 
temperature  was  0~  Curve  C:  Identical to curve A, 
except that  the dissociation  temperature  was 0~  The 
results  are expressed as the relative percentage of cell- 
bound  radioactivity  remaining  at  the  indicated  times, 
taking as 100% the amount of radioactivity present after 
the initial binding period. 
TABLE IV 
Nature of Cell-Bound ~251-hEGF  Released 
into Medium 
Radioactivity  released 
Temperature  Time interval  High mol wt  Low tool wt 
37~ 
h  %  % 
0.0-0.5  32  68 
0.5-2.0  10  90 
0~  0.0-2.0  >99  < 1 
2.0-8.0  >99  <1 
~zSI-hEGF (1.6  ng/ml, 24,700  cpm/ng) was  allowed to 
bind to confluent cultures of HF fibroblasts  at 37~  for 
40  min or at 0~  for 60  min; approximately 5,000  or 
1,000 cpm of 1251-hEGF were bound, respectively. The 
culture dishes were then washed free of unbound hEGF 
with Hanks' solution, 2 ml of the standard binding me- 
dium were re-added, and the cultures were incubated at 
the indicated temperatures. The medium, containing the 
released radioactivity, was collected at the intervals indi- 
cated and lyophilized. The distribution  of the radioactiv- 
ity in  each sample was  examined by gel filtration (see 
text), using portions containing 400-5,000 cpm of ~zsI. 
Inhibition of Degradation of Cell- 
Bound 12SI.hEGF 
To investigate the  mechanisms  involved in  the 
rapid,  cell-mediated  degradation  of  125I-labeled 
hEGF,  we  attempted,  by  a  variety of means,  to 
inhibit  this  process.  Previous  studies  (2)  have 
shown  that  the  trypsin  inhibitors  tosyl-L-lysine 
chloromethyl ketone and the benzyl ester of guan- 
idobenzoic acid inhibited  the  degradation  of ~z~I- 
mEGF by human fibroblasts. The data in Table V 
(exp  1)  show  that  these  protease  inhibitors  also 
block the degradation  of 125I-hEGF. 
If the degradation  of tzsI-hEGF involves an en- 
ergy-dependent form of internalization of the cell- 
bound  growth  factor,  inhibitors  of metabolic en- 
ergy should  prevent  this  process.  Therefore,  the 
effects  of  a  number  of  inhibitors  of  metabolic 
energy production on the initial binding (40 rain, 
37~  of ~zsI-hEGF to HF cells and the subsequent 
loss  of  cell-bound  radioactivity  were  examined. 
No appreciable  effects on these parameters  were 
noted  when  dinitrophenol  and  sodium  fluoride 
were added to the standard binding medium which 
contained both glucose and amino acids (Table V, 
exp  2).  In  a  medium  lacking  both  glucose  and 
amino  acids,  however,  dinitrophenol,  sodium 
azide, or sodium cyanide  was effective in slowing 
the  loss  of cell-bound  radioactivity but  had  little 
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Inhibition of the Release  of Cell-Bound I~I-hEGF 
Zero time  Cell-bound 
Exp.  radioac-  n~I-hEGF 
no.  tivity  Addition  after 2 h 
cpm  %  initial value 
1  6,511  None  9 
9,504  Tos-LysCH~CI  (50 ~g/ml)  57 
8,325  Tos-LysCH2CI (5 izg/ml)  46 
9,819  Benzyl guanidobenzoate  (100  53 
/zg/ml) 
7,567  Benzyl  guanidobenzoate (10/zg/  12 
ml) 
2  6,159  None  7 
6,790  Dinitrophenol (0.5 mM)  10 
5,970  Sodium fluoride (1 raM)  8 
6,899  Dinitrophenol (0.5 raM) plus so-  10 
dium fluoride (1 raM) 
3  4,110  None  20 
4,131  Dinitrophenol (1 raM)  73 
4,041  Dinitrophenol (0.5 raM)  67 
4,200  Sodium azide (5 mM)  52 
3,996  Sodium azide (1 raM)  19 
4,581  Sodium cyanide (5 raM)  48 
4,062  Sodium cyanide (1 mM)  26 
4  3,445  None  12 
3,741  Chloroquine (0.1 mM)  72 
3,966  Chloroquine (0.01  raM)  35 
2,712  Lidocaine (5 mM)  70 
3,213  Lidocaine (1 raM)  66 
3,278  Cocaine (1 mM)  78 
3,883  Procaine  (I mM)  64 
3,941  Procaine  (0.1 mM)  15 
3,758  Ammonium chloride (10 raM)  98 
3,649  Ammonium chloride (2 raM)  67 
Fibroblasts (0.8  to  1.0  x  10  ~ cells/dish) were preincubated  in  1.5  ml of 
binding medium* with the indicated compounds at 37"C. The preincubation 
period was 60 rain for exp 1, 30 min for exp 2 and 3, and 15 min for exp 4. 
At the  end of the  preincuhatinn  period,  ml-hEGF was added  at a final 
concentration  of 2-4  ng/ml  for  a  40-rain  binding period  at  37"C. The 
cultures subsequently were washed eight  times with a  total  of 15  ml of 
Hanks'  solution containing 0.1%  albumin, and  1.5 ml of the binding me- 
dium, with the indicated compounds, were added. The call-bound radioac- 
tivity present at this time was taken as the zero-time control value. Then the 
culture dishes were incubated for 2 h at 37"C, washed four times with a total 
of  8  ml  of cold  Hanks'  solution,  and  the  cell-bound  radioactivity  was 
measured. 
* The standard binding medium (see Materials and Methods) was employed 
in exp  1, 2, and 4. The binding and washing medium employed in exp.  3 
consisted of glucose-free Hanks' solution containing 0.1%  albumin and 20 
mM HEPES buffer, pH 7.5. 
influence on the amount of initial binding (Table 
V, exp 3). The results suggest that the degradation 
of  ~25I-hEGF,  under  these  experimental  condi- 
tions, is dependent on the generation of metabolic 
energy. 
To examine the possibility that the proteolysis 
required for the liberation of ~2~I-labeled monoio- 
dotyrosine from cell-bound ~zSI-hEGF may be me- 
diated by  lysosomal hydrolases, we  investigated 
the effect of chloroquine, which is reported to be 
concentrated rapidly into lysosomes by fibroblasts 
and to inhibit lysosomal enzyme activities (9, 24, 
36), on the binding and degradation of 125I-hEGF. 
As shown  in  Table  V  (exp 4),  0.1  mM  chloro- 
quine produced a considerable amount of inhibi- 
tion of degradation, suggesting that the proteolytic 
activity of lysosomal enzymes may indeed be in- 
volved in the cellular metabolism of hEGF. 
Unexpectedly, we found that local anesthetics, 
such  as  procaine, iidocaine, and  cocaine, which 
are reported to interact with cell-surface compo- 
nents (27, 29, 32), also inhibited the degradation 
of cell-bound 125I-hEGF  (Table  V,  exp 4).  The 
inhibitory effects were observed at concentrations 
of these reagents which had no apparent effect on 
the morphological appearance of HF cells as seen 
by  light  microscopy.  The  possibility that  these 
local anesthetics, which are tertiary amines, may 
inhibit degradation by a mechanism similar to that 
of chloroquine, which is also a  tertiary amine, is 
considered in a later section. 
In this regard, it is of interest that ammonium 
chloride at concentrations of 2-10 mM has been 
reported to inhibit protein degradation in isolated 
hepatocytes (33).  Within the same range of con- 
centrations, ammonium chloride was a potent in- 
hibitor of the degradation of cell-bound 125I-hEGF 
(Table V, exp 4). 
Since the radioactivity bound to the cells after a 
40-min incubation at 37~  was a result of the total 
amount  of  12SI-hEGF  bound  during  this  period 
minus the  amount  of radioactivity lost from the 
cell due to degradation, it was expected that the 
presence of inhibitors of the degradation process 
would result in an increase in the initial level of 
radioactivity bound to the cell. The data in Table 
V show that, in general, the presence of inhibitors 
of degradation does result in  an  increase in  the 
extent  of  initial  binding  of  the  labeled  growth 
factor. 
Internalization of Cell-Bound 125I-hEGF 
Three experiments were performed to provide 
evidence,  albeit  indirect,  that  cell-bound  t25I- 
hEGF is internalized before degradation. The ra- 
tionale for these experiments is that, if internaliza- 
tion (endocytosis?) of membrane-bound hormone 
is minimized by lowering the temperature to 0~ 
the accessibility of the membrane-bound hormone 
to  reagents  in  the  medium,  such  as  trypsin  or 
antibodies to hEGF, will be increased. 
The experiment reported in Fig. 5 demonstrates 
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bind  to cells which  had been pre-incubated  with 
hEGF at 0~  The capacity of these hEGF-treated 
cells to bind antibody was rapidly lost upon warm- 
ing to  37~  for brief periods  of time  (1-8  min), 
Control experiments  demonstrating  that  the hor- 
mone remained associated with the cells were car- 
ded out, under the conditions described for Fig. 5, 
with J2SI-labeled hEGF. The half-life for the disap- 
pearance  of antibody  binding  was approximately 
1-2 min. 
The  experiment  shown  in  Table  VI  indicates 
that  approximately  50%  of the  x25I-hEGF bound 
at  0~  to  the  cells was  liberated  by  trypsin,  but 
only 10%  of the 125I-hEGF bound at 37~  to the 
cells was released by the same treatment. 
The data  in Fig. 4  demonstrate  that,  when the 
labeled hormone  was bound  to the cells at 37~ 
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FmURE 5  Binding of l~SI-labeled rabbit hEGF-antise- 
rum to fibroblasts  preincubated with hEGF. Unlabeled 
hEGF (6 ng/ml) was added to the culture dishes contain- 
ing  2  ml of the  binding  medium  at  0~  After a  2-h 
incubation,  the  cells  were  washed  free  of  unbound 
hEGF, and 2 ml of binding medium were re-added, nsI- 
labeled antiserum to hEGF (0.75/~g, 3  x  106 cpm//~g) 
was added and the cultures were re-incubated for 90 min 
at  0~  Then  the  cultures  were  washed  and  the  cell- 
bound radioactivity was determined; the amount of ra- 
dioactivity present (corrected for "nonspecific" binding) 
was taken as 100%. Replicate cultures, taken just before 
the addition of antiserum, were incubated at 37"C for the 
indicated time intervals, re-chilled, and then tested for 
their ability to bind the ~25I-labeled antiserum. The radio- 
activity  which  was  cell-bound in the absence  of added 
hEGF was considered to be the "nonspecific blank" and 
was subtracted from the experimental values obtained. 
In separate experiments, this  "blank" value of approxi- 
mately  3,000  cpm/dish  amounted  to  25-50%  of the 
value obtained in the presence of hEGF. 
TABLE VI 
Effect of Cold Trypsinization on the Release of Cell- 
Bound x~I-hEGF 
Percentage of radioactivity 
Bmdmg  Exp 
temperatu~  no.  Cell peHet  Supemate 
%  % 
37~  1  90  10 
2  90  10 
0~  1  46  54 
2  61  39 
XZ~l-hEGF (6 ng/ml, 33,000 cpm/ng) was allowed to bind 
to confluent cultures of HF fibroblasts  at 37~  for 40 rain 
or at 0~  for 60 min. The culture dishes then were chilled 
on ice and washed free of unbound ~25I-hEGF using cold 
Hanks' solution. To each dish, 1 ml of 0.25% trypsin  (in 
GIBCO  solution  A  containing  0.1%  albumin)  was 
added, and the dishes were incubated for 30 min on ice. 
Serum-containing DM medium (0.5 ml) then was added, 
and the detached cells were suspended and centrifuged. 
The supernatant  fluid was  carefully aspirated,  and  the 
radioactivity present in both the cell pellets and super- 
hates was measured. 
the expected release of the cell-associated radioac- 
tivity, either  as  iodotyrosine  or undegraded  hor- 
mone,  did  not  occur when  the  temperature  was 
lowered  to  0~  (compare  curve  C  with  either 
curve A  or B). All of these results are consistent 
with  a  mechanism  in  which  x25I-hEGF initially is 
bound to the cell surface and subsequently is inter- 
nalized prior to degradation. 
Recovery of hEGF Binding Capacity 
The  results  of previous  experiments  indicated 
that  following  the  binding  and  degradation  of 
hEGF, human fibroblasts were capable of rebind- 
ing only a  small  quantity  of fresh  hormone  (ap- 
proximately  10-20%  of  the  initial  value).  The 
following experiment  was performed  to  examine 
the kinetics of and the metabolic requirements for 
the  recovery of hEGF-binding  capacity  by  these 
cells. The binding sites on replicate cultures of HF 
ceils  were  saturated  with  unlabeled  EGF,  un- 
bound hormone was removed, and the cell-bound 
EGF was allowed to degrade. The time-course of 
the  recovery of hEGF-binding capacity  by  these 
cells, in the presence and absence of serum and in 
the presence  of cycloheximide or actinomycin  D, 
was examined (Fig.  6).  The results indicate that: 
(a)  approximately  10  h  of  incubation  in  serum- 
containing  medium  were  required  for  the  com- 
plete recovery of the initial hEGF binding capac- 
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FIGURE 6  Recovery of hEGF binding capacity  in fi- 
broblasts. An excess of unlabeled mEGF (1 /zg/ml) was 
added to replicate culture dishes containing 1.5 ml of the 
standard binding medium at 37~  After a  1-h period, 
the cells were washed to remove unbound mEGF, 1.5 ml 
of the binding medium were re-added, and the cultures 
were incubated for 4 h at 37~  to permit degradation of 
the  bound hormone. Then the  medium was  replaced 
with one of the following: (a)  DM plus 0.1%  albumin 
(￿9169  (b) DM plus 10% calf serum (t--Q), (c) DM 
plus  10%  calf  serum  plus  cycloheximide  (20  /xg/ml) 
(A--A), or (d) DM plus 10% calf serum plus actinomy- 
cin D (1 /zg/ml) (D--O). At the indicated times, dupli- 
cate dishes from each group were selected,  washed, and 
assayed for their binding capacity for tZSl-hEGF (6 ng/ 
ml) in the standard binding medium (40 rain at 37~ 
The extent of lzsI-hEGF binding  in replicate cultures, not 
exposed to mEGF, was taken as 100%, and the results 
are expressed  as the relative percentage of cell-bound 
radioactivity. 
ity; and (b) the synthesis of both protein and RNA 
was required for the reappearance of hEGF bind- 
ing in these cells. 
DISCUSSION 
Many of the  characteristics  of the  interaction of 
125I-labeled  hEGF with human fibroblasts are sim- 
ilar to  those  previously reported  for  125I-labeled 
mouse EGF (2). Both polypeptides bind rapidly to 
HF cells at 37~  appear to compete for the same 
binding sites on these cells, and subsequently are 
degraded  upon  prolonged  incubation. The  con- 
centrations  of  each  polypeptide  required  to 
achieve  maximal binding were  similar (1.5-2  ￿ 
10  -9 M) and were  approximately fourfold higher 
than the concentrations required (3.7  ￿  10  -1~ M 
for hEGF and  8  x  10  -1~ M  for  mEGF) for  the 
maximal stimulation of  [3H]thymidine incorpora- 
tion  into  confluent  cultures  of  fibroblasts  (7). 
These  values  are  in  reasonable  agreement  with 
those reported for mEGF by Hollenberg and Cua- 
trecasas  (20),  using a  different  strain  of  human 
fibroblasts and slightly different experimental con- 
ditions  (1.3  x  10  _9  M  and  3.3  x  10 -1~ M  for 
saturation of binding and maximal stimulation of 
thymidine incorporation, respectively). The  data 
indicate that only a fraction (less than 25%) of the 
available EGF-binding sites need to be occupied 
for cells arrested in the G1 phase of the cell cycle 
to enter the S phase. 
After a  brief incubation of 125I-hEGF with HF 
cells  at  37~  acid  extraction  of  the  cells yields 
radioactive material which seems to be identical to 
native 1zSI-hEGF, based on the binding affinity to 
fresh cells and on gel filtration studies. It appears, 
therefore,  that  the  native form of the  125I-hEGF 
molecule binds to  the  cell surface  receptors  and 
that  its  structure  is  not detectably altered  in an 
irreversible  manner  by  the  binding  process. 
Mouse-derived EGF bound to liver and placental 
membranes in vitro has been extracted and found 
to rebind to fresh membranes (25). The extraction 
of  other  polypeptide  hormones  bound  to  intact 
cells (8, 11, 23, 35) or plasma membrane prepara- 
tions (13, 30) has yielded similar results. 
Experiments reported herein indicate that, after 
the  binding of hEGF to the cell surface at 37~ 
the hormone is rapidly internalized and degraded. 
This process most likely occurs via the endocytotic 
formation  of  pinosomes  containing  membrane- 
bound hEGF, fusion of the pinosomes with lyso- 
somes,  and  degradation  of  hEGF  by  lysosomal 
proteases. 
The ability of 125I-labeled  mouse EGF to bind in 
a  reversible  manner to  cell  membrane  prepara- 
tions has been reported (25). The reversible bind- 
ing of ~25I-labeled hEGF is also demonstrable with 
intact  human fibroblasts,  provided  the  tempera- 
ture is kept at 0~  In contrast,  most of the cell- 
bound radioactivity is released as monoiodotyro- 
sine during incubation at 37~ 
All of our experiments are consistent with the 
hypothesis that membrane-bound IzSI-hEGF is in- 
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is bound to the cells at 0~  much of it is released 
by trypsin; when the hormone is bound at 37~ 
very little is released by trypsin (Table VI). Fur- 
ther, cells preincubated with hEGF at 0~  are able 
to bind antibodies to hEGF; the ability of these 
hEGF-treated cells to bind antibodies is lost rap- 
idly upon  warming,  with  a  half-life of  1-2  min 
(Fig. 5). Finally, cell-bound hEGF neither disso- 
ciates nor is degraded when the hormone initially 
is  bound  at  37~  and  the  temperature  subse- 
quently is lowered to 0~  (Fig. 4). 
These results indicate that hEGF bound to cells 
at  low  temperature  (which  inhibits endocytosis) 
exists as an intact molecule primarily on  the cell 
surface, and that both internalization and degra- 
dation are temperature dependent. We also have 
demonstrated that the degradation of cell-bound 
hEGF  requires  the  production  of metabolic en- 
ergy (Table V, exp 3);  it is unlikely that plasma 
membrane-mediated proteolysis would be energy 
dependent. Endocytosis has been shown by others 
to be an energy- and temperature-dependent proc- 
ess (34). 
The evidence presented in this paper indicates 
that concomitant with the internalization of cell- 
bound hEGF, most of the membrane receptors for 
this  polypeptide are  inaccessible to  added  fresh 
hormone.  The  data  in  Fig.  1  show  that,  in  the 
continuous  presence  of  nanogram  quantities  of 
~zSI-hEGF at 37~  the capacity of the cells to bind 
the hormone decreases to approximately 15%  of 
the  initial value after 6  h  of incubation.  Similar 
results were obtained (Fig. 6) when the cells were 
preincubated  with  a  saturating amount  of unla- 
beled mEGF, washed, incubated for 4  h to allow 
membrane-bound  hormone  to be degraded, and 
tested  for  their  ability to  bind  fresh  ~25I-hEGF. 
Binding capacity was reduced to 26% of the initial 
value. The  decreased ability of the  ceils to bind 
~zSI-hEGF either in the continuous presence of the 
hormone or following binding and degradation of 
the  unlabeled  hormone  suggests  that  either  the 
entire  hormone-receptor  complex  has  been  re- 
moved from  the  membrane  or that  the  receptor 
has  been  inactivated  or  masked.  We  have  not 
been  able,  as  yet,  to  distinguish experimentally 
between these alternatives. The decreased ability 
of the  cells to  bind  ~2SI-hEGF  is a  hormone-de- 
pendent phenomenon; binding capacity is not re- 
duced  by  incubation  of the  cells in  the  binding 
medium for 6 h. The return of binding capacity in 
the presence  of serum  and  the  inhibition of this 
recovery by cycloheximide or actinomycin D  (Fig. 
6) suggest that the receptor is resynthesized after 
endocytosis  of  the  hormone-receptor  complex. 
The possibility  that protein and RNA synthesis are 
required for the recycling of "old" receptors has 
not been excluded. Evidence for the regulation of 
the concentration of membrane receptors by insu- 
lin (14),  thyrotropin-releasing hormone  (19),  a- 
bungarotoxin (10), concanavalin A  (26), and Rici- 
nus communis  agglutinin (26) has been reported. 
The  major  product  of  degradation  of  x~I-lao 
beled  hEGF  which  appears  in  the  medium  is 
[125I]monoiodotyrosine. Similar results have been 
reported for the degradation of other cell-bound 
125I-labeled proteins (10, 15) including mEGF (2). 
That the proteolytic process occurs following the 
fusion of endocytotic pinosomes with lysosomes is 
indicated by inhibition of degradation by certain 
agents whose mode of action is suspected to be the 
inhibition of lysosomal enzymes. As shown in Ta- 
ble V, chloroquine inhibits the degradation of lzsI- 
labeled  hEGF.  The  lysosomotropic  action  of 
chloroquine  recently has  been  discussed  by  De 
Duve et al. (9). Lie and Schofield (24) have shown 
that chloroquine blocks the lysosomal degradation 
of mucopolysaccharides in human fibroblasts, and 
Goldstein et al.  (16)  have  reported that  chloro- 
quine inhibits the degradation of 125I-labeled  low 
density lipoproteins by human  fibroblasts. Wibo 
and  Poole  (36)  have  shown  that  chloroquine  is 
concentrated rapidly within rat fibroblasts and in- 
hibits the  degradation of cellular protein. These 
authors  also  demonstrated  that  chloroquine  in- 
hibits  the  enzymatic  activity of cathepsin  B1  in 
vitro. 
Recently, Seglen (33) has reported that protein 
degradation in rat hepatocytes is inhibited by am- 
monium chloride. The data in Table V  show that 
ammonium  chloride is a  potent  inhibitor of the 
degradation of 125I-labeled  hEGF.  We also have 
found that local anesthetics such as cocaine, pro- 
caine,  and  lidocaine  inhibit  the  degradation  of 
hEGF. 
Although there  is no  evidence to  indicate the 
manner in which protein degradation is inhibited 
by ammonia or local anesthetics, it is possible that 
their mode of action may be similar to that sug- 
gested for chloroquine. All of these inhibitors are 
lipid  soluble  and  permeable  to  cellular  mem- 
branes. The  data of Wibo and  Poole  (36)  show 
that chloroquine is concentrated several hundred 
fold within lysosomes, and Papahadjopoulis et al. 
(27) have shown that local anesthetics have a high 
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branes and aqueous buffer. In un-ionized form, 
ammonia  would  also  be  able  to  permeate  cell 
membranes. A  unifying hypothesis for the inhibi- 
tion of degradation of 125I-labeled hEGF by these 
various  agents  is  suggested  by  the  fact  that  at 
physiological pH these compounds contain amine 
groups  that  are  not  fully  protonated.  If  these 
agents are able to permeate the lysosomal mem- 
brane,  the  intralysosomal concentrations would 
increase as the amino groups become protonated 
due to the low pH inside the lysosome. Presum- 
ably,  the  protonated  species  would  then  be 
trapped inside the lysosome and the internal pH of 
the organelle would be increased, resulting in de- 
creased activity of hydrolytic lysosomal enzymes. 
This hypothesis has  been introduced by Home- 
wood et al. (21) and reviewed by De Duve et al. 
(9) to explain the lysosomotropic activity of chlor- 
oquine. We suggest that ammonia and local anes- 
thetics may also act in this manner. Poste et al. 
(29) have concluded that local anesthetics influ- 
ence the activity of peripheral membrane proteins 
and that the addition of Ca  ++ negates the effects of 
local  anesthetics  in  their  experimental systems. 
However,  we  do  not find that  Ca  ++  affects  the 
inhibition of 'zSI-labeled hEGF degradation (data 
not shown), which suggests for local anesthetics a 
mode  of action different from  that  observed  in 
other systems. 
Although the  experiments reported  here  indi- 
cate that human fibroblasts are capable of binding, 
internalizing,  and  degrading  hEGF,  it  is  not 
known whether  internalization, with  or  without 
degradation, is required in order to  elicit an in- 
crease  in  the  synthesis of  DNA  or  is  simply a 
mechanism for the  inactivation of the  hormone. 
Any molecular explanation for the mitogenic ef- 
fect of hEGF must take into account the observa- 
tion that hEGF must be present in the medium for 
an extended period of time, much longer than the 
time required to saturate the binding sites, in or- 
der to observe a stimulation  of DNA synthesis (3). 
If there are transient alterations in metabolic pa- 
rameters as a consequence of the initial binding of 
the hormone by the fibroblasts, these would not 
appear to be sufficient for the initiation  of a round 
of DNA replication. The exposure of the fibro- 
blasts to hEGF appears to result in the removal of 
most  of  the  surface  receptors  for  this  mitogen. 
After approximately 6 h at 37~  (Fig. 1), a steady- 
state equilibrium is apparently achieved in which 
10-20% of the receptor sites, initially  available for 
binding, remain on the surface. Whether this is a 
result of the recycling of old receptors, the synthe- 
sis of new receptors, or the inability  of some of the 
receptors to be internalized is not known. In an 
experiment similar to that described in Fig. 1, we 
have  examined  the  metabolic  fate  of  the  cell- 
bound 125I-hEGF remaining after 6  h  of incuba- 
tion; upon removal of unbound hormone by the 
addition of fresh medium, 70-80% of the bound 
I~I-hEGF was still degradable to monoiodotyro- 
sine, albeit at a somewhat slower rate (tl/2 approx- 
imately 1 h, data not shown). Thus, the cell-bound 
12~I-hEGF which is detectable after 6 h of incuba- 
tion degrades  in a  manner essentially similar to 
that  of the hormone initially bound. These data 
suggest that  the  low steady-state level of bound 
hormone observed after 6-h incubation at 37~  is 
not due to a  unique class of receptors which are 
unable to internalize bound hormone. 
Received  for publication  31  December  1975,  and in re- 
vised form 5 May 1976. 
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